Klinikum Bielefeld gGmbH — Clinical Trial Site

37 Registered trials

13 Currently recruiting

Organisation

Klinikum Bielefeld gGmbH

Location

Bielefeld, Germany

Identifier

ORG-100044317

Address

Teutoburger Strasse 50, Innenstadt, 33604, Germany

Departments

#3408: Klinik für Kardiologie und internistische Intensivmedizin
#6005; Klinik für Dermatologie, Venerologie und Allergologie
2200: Abteilung für Kardiologie und internistische Intensivmedizin
3408: Klinik für Kardiologie und internistische Intensivmedizin
40891: Klinik für Dermatologie, Venerologie und Allergologie
Abteilung für Kardiologie und internistische Intensivmedizin
Apotheke
Centre for Gynaecology
Clinic for Dermatology, Venerology and Allergology
Clinic for DermatologyVenerology and Allergology
Department of Dermatology, Venerology and Allergology
Dermatology
Dermatology and Venerology
Dermatology, Venerology and Allergology
Hämatologie, Onkologie & Palliativmedizin
Hautklinik
Klinik für Allgemein- und Viszeralchirurgie
Klinik für Dermatologie, Venerologie und Allergologie
Klinik für Dermatologie, Venerologie und Allergologie Studienzentrum Rosenhöhe
Klinik für Hämatologie und Onkologie
Klinik für Hämatologie, Onkologie und Palliativmedizin
Klinik für Hämatologie, Onkologie, Palliativmedizin und Stammzelltherapie
Klinik für Onkologie, Hämatologie und Palliativmedizin
Klinik für Onkologie, Hämatologie, Palliativmedizin
Klinische Forschung
N/A
na
Onkologie/Hämatologie /Palliativmedizin
Universitätsklinik für Endokrinologie und Diabetologie, Allgemeine Innere Medizin, Infektiologie
Universitätsklinik für Kardiologie und internistische Intensivmedizin

Clinical trials at this site (37)

Search interface

An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
A study to learn how safe bimekizumab is and how well it works in adults with palmoplantar pustulosis Recruiting

2024-520337-80-00 Palmoplantar Pustulosis 5 2026-01-07
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
NeoMatryx - Neoadjuvant Merkel cell carcinoma therapy (Tx) with the PD-1 inhibitor Cemiplimab – A randomized, double-blind, placebo-controll… Recruiting

2025-522091-84-00 Merkel Cell Carcinoma 4 2026-05-29
Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE) Recruiting

2025-522403-17-00 Nummular Dermatitis 5 2026-04-10
Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting

2024-516356-18-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-02-17
ZANGEA – Phase II Study of Zanidatamab in Combination with Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesopha… Recruiting

2025-522718-22-00 Gastroesophageal Adenocarcinoma 4 2025-12-16
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting

2025-520564-17-00 Hidradenitis suppurativa (HS) 5 2025-10-16
A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig… Recruiting

2025-520519-14-00 Atherosclerotic Cardiovascular Disease 5 2025-09-03
Venetoclax plus azacitidine versus standard intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and NPM1 m… Recruiting

2024-515267-59-00 Acute myeloid leukemia 4 2024-04-07
Expression-linked and R-ISS-adapted stratification for first line therapy in multiple myeloma patients (ELIAS) Recruiting

2022-500453-16-00 Multiple Myeloma 4 2023-10-30
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line tr… Recruiting

2024-512320-11-00 Primary diffuse large B-cell lymphoma of the central ne 5 2023-08-09
HIPEC/FLOT9 - PREVENT Recruiting

2024-517300-10-01 Resectable diffuse type gastric and gastroesophageal ju 5 2020-12-17
A study to test whether vicadrostat in combination with empagliflozin helps people with chronic kidney disease Ended

2024-518457-42-00 chronic kidney disease 4 2025-08-28
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended

2023-506876-28-00 The medical condition we are investigating is type 1 AM 5 2024-08-01
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o… Ended

2022-502518-98-00 nonsegmental vitiligo 5 2024-04-26
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+… Ended

2024-514458-61-01 HER2+ early breast cancer 4 2024-02-05
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined… Ended

2024-511577-29-01 intermediate and high-risk rectal cancer 5 2020-03-13
A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit… Ended

2023-508292-37-00 Cardiovascular Disease 5 2020-03-06
DANTE / FLOT8 A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in … Ended

2024-514945-12-00 locally advanced resectable adenocarcinoma of the oesop 10 2018-09-03